News | June 23, 2026
Teva closes $700M Emalex acquisition
Bolstering neuroscience push with late-stage Tourette therapy
Bolstering neuroscience push with late-stage Tourette therapy
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
Patnaik stressed early diagnosis, rapid treatment, and aggressive surveillance as the backbone of elimination efforts
Samelisant will be the centerpiece of Suven’s scientific presence
The regulatory decision follows promising results from RIVER-81
Subscribe To Our Newsletter & Stay Updated
